Home › Compare › YMTX vs O

YMTX vs O: Dividend Comparison 2026

YMTX yields 105.82% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YMTX wins by $4.89M in total portfolio value
10 years
YMTX
YMTX
● Live price
105.82%
Share price
$1.89
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.93M
Annual income
$1,723,843.10
Full YMTX calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — YMTX vs O

📍 YMTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYMTXO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YMTX + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
YMTX pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMTX
Annual income on $10K today (after 15% tax)
$8,994.71/yr
After 10yr DRIP, annual income (after tax)
$1,465,266.64/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, YMTX beats the other by $1,460,933.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMTX + O for your $10,000?

YMTX: 50%O: 50%
100% O50/50100% YMTX
Portfolio after 10yr
$2.48M
Annual income
$864,470.65/yr
Blended yield
34.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

YMTX
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-21.9
Piotroski
3/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.6% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMTX buys
0
O buys
0
No recent congressional trades found for YMTX or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYMTXO
Forward yield105.82% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$4.93M$34.2K ✓
Annual income after 10y$1,723,843.10 ✓$5,098.20
Total dividends collected$4.43M$20.7K ✓
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: YMTX vs O ($10,000, DRIP)

YearYMTX PortfolioYMTX Income/yrO PortfolioO Income/yrGap
1← crossover$21,282$10,582.01$10,818$607.86+$10.5K → YMTX
2$43,819$21,047.33$11,786$741.30+$32.0K → YMTX
3$87,387$40,500.83$12,944$910.50+$74.4K → YMTX
4$168,990$75,485.74$14,343$1,127.28+$154.6K → YMTX
5$317,245$136,425.12$16,053$1,408.17+$301.2K → YMTX
6$578,807$239,355.52$18,167$1,776.65+$560.6K → YMTX
7$1,027,455$408,130.85$20,815$2,266.60+$1.01M → YMTX
8$1,776,463$677,086.81$24,179$2,927.66+$1.75M → YMTX
9$2,994,908$1,094,092.83$28,521$3,833.95+$2.97M → YMTX
10$4,928,395$1,723,843.10$34,218$5,098.20+$4.89M → YMTX

YMTX vs O: Complete Analysis 2026

YMTX — Stock

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Full YMTX Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this YMTX vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMTX vs SCHDYMTX vs JEPIYMTX vs KOYMTX vs MAINYMTX vs STAGYMTX vs ADCYMTX vs NNNYMTX vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.